Novartis heart failure drug found to be effective across patient groupsGlobal TimesAn experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical…
Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 – PR Newswire (press release)
Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023PR Newswire (press release)Read on, then, to explore biosimilar monoclonal antibodies (mAbs) and see what their future market could be worth. Forecasts to 2023 and other analyses show yo…
DPP-4 do not Raise Heart Attack Risk, but Associated with Heart Failure – French Tribune
French TribuneDPP-4 do not Raise Heart Attack Risk, but Associated with Heart FailureFrench TribuneAs per a research, it has been unveiled that diabetes pills known as DPP-4 has been found to not to raise risk of heart attack. It was said in the past t…
Automatic Wireless Monitoring Shows Benefits in Chronic Heart Failure – Forbes
Automatic Wireless Monitoring Shows Benefits in Chronic Heart FailureForbesFollowing in the wake of studies that failed to find benefits associated with remote wireless monitoring of heart failure (HF) patients, the In-Time trial, presented at the Euro…
Chronic Kidney Disease Market: 81M CKD Cases by 2022 Says a New … – Watch List News (press release)
Chronic Kidney Disease Market: 81M CKD Cases by 2022 Says a New …Watch List News (press release)When the kidneys fail in the advanced stages of CKD, patients are advised to undergo renal replacement therapy (RRT), which includes renal dialysis and ki…
Hamad medical corporation performs third successful spousal kidney transplant – Al-Bawaba
|
Hamad medical corporation performs third successful spousal kidney transplant
Al-Bawaba “We encourage all our patients on the waiting list for kidney transplantation to look for donors among their relatives, as this is not only safe but is also faster than waiting for a deceased donation. We have an excellent transplant record with zero … |
Novartis heart failure drug effective across patient groups – Reuters India
|
Novartis heart failure drug effective across patient groups
Reuters India AMSTERDAM (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed. The drug … Novartis heart failure drug found to be effective across patient groupsGlobal Times Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple …ITNews Novartis: RLX030 Improved Symptoms, Mortality In Heart PatientsNASDAQ |
Chronic Kidney Disease Market: 81M CKD Cases by 2022 Says a New … – PR Web (press release)
Chronic Kidney Disease Market: 81M CKD Cases by 2022 Says a New …PR Web (press release)Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function o…
Novartis heart failure drug effective across patient groups – Reuters UK
|
Novartis heart failure drug effective across patient groups
Reuters UK AMSTERDAM (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed. The drug … Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple …ITNews Novartis: RLX030 Improved Symptoms, Mortality In Heart PatientsNASDAQ Novartis: RLX030 Found Effective Across Multiple Subgroups Of Heart PatientsRTT News |
Novartis heart failure drug effective across patient groups – Reuters
Business Recorder |
Novartis heart failure drug effective across patient groups
Reuters Serelaxin works across sub-groups, study results show. * Heart failure drug viewed as potential blockbuster. By Ben Hirschler. AMSTERDAM, Sept 2 (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless … More data backs Novartis’ serelaxin in heart failurePMLiVE |